Radiotherapy & Oncology
Volume 86, Issue 3 , Pages 295-299 , March 2008

Clinical radiobiology in 2008

  • Adrian Begg

      Affiliations

    • Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    • ,
  • Albert van der Kogel

      Affiliations

    • Department of Radiation Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • Corresponding Author InformationCorresponding author. Albert van der Kogel, Department of Radiation Oncology, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

Received 1 February 2008 ,Revised 1 February 2008 ,Accepted 1 February 2008.

References 

  1. Aerts HJ, Dubois L, Hackeng TM, Straathof R, Chiu RK, Lieuwes NG, et al. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol. 2007;83:326–332
  2. Alsner J, Rødningen OK, Overgaard J. Differential gene expression before and after ionizing radiation of subcutaneous fibroblasts identifies breast cancer patients resistant to radiation-induced fibrosis. Radiother Oncol. 2007;83:261–266
  3. Baumann M, Krause M, Dikomey E, Dittmann K, Dörr W, Kasten-Pisula U, et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol. 2007;83:238–248
  4. Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol. 2007;83:220–230
  5. Dewhirst MW, Cao Y, Li CY, Moeller B. Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol. 2007;83:249–255
  6. Dubois L, Douma K, Supuran CT, Chiu RK, van Zandvoort MA, Pastorekova S, et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol. 2007;83:367–373
  7. Eriksen JG, Overgaard J Danish Head and Neck Cancer Study Group (DAHANCA). Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol. 2007;83:383–388
  8. Kasten-Pisula U, Windhorst S, Dahm-Daphi J, Mayr G, Dikomey E. Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis. Radiother Oncol. 2007;83:296–303
  9. Koritzinsky M, Rouschop KM, van den Beucken T, Magagnin MG, Savelkouls K, Lambin P, et al. Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol. 2007;83:353–361
  10. Krause M, Prager J, Zhou X, Yaromina A, Dörfler A, Eicheler W, et al. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells?. Radiother Oncol. 2007;83:316–325
  11. Lavin MF, Kozlov S. DNA damage-induced signalling in ataxia-telangiectasia and related syndromes. Radiother Oncol. 2007;83:231–237
  12. Magagnin MG, Sergeant K, van den Beucken T, Rouschop KM, Jutten B, Seigneuric R, et al. Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiother Oncol. 2007;83:340–345
  13. Meyer A, Wilhelm B, Doerk T, Bremer M, Baumann R, Karstens JH, et al. ATM missense variant P1054R predisposes to prostate cancer. Radiother Oncol. 2007;83:283–288
  14. Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR, Overgaard J. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol. 2007;83:389–397
  15. Rachidi W, Harfourche G, Lemaitre G, Amiot F, Vaigot P, Martin MT. Sensing radiosensitivity of human epidermal stem cells. Radiother Oncol. 2007;83:267–276
  16. Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83:398–405
  17. Schütze C, Bergmann R, Yaromina A, Hessel F, Kotzerke J, Steinbach J, et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol. 2007;83:311–315
  18. Seigneuric R, Starmans MH, Fung G, Krishnapuram B, Nuyten DS, van Erk A, et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol. 2007;83:374–382
  19. van den Beucken T, Magagnin MG, Savelkouls K, Lambin P, Koritzinsky M, Wouters BG. Regulation of Cited2 expression provides a functional link between translational and transcriptional responses during hypoxia. Radiother Oncol. 2007;83:346–352
  20. Weppler SA, Li Y, Dubois L, Lieuwes N, Jutten B, Lambin P, et al. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol. 2007;83:333–339
  21. Wiegman EM, Blaese MA, Loeffler H, Coppes RP, Rodemann HP. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiother Oncol. 2007;83:289–295
  22. De Schutter H, Barbé B, Spaepen M, Begg AC, Balm A, Gregoire V, et al. Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1. Radiother Oncol. 2006;80:143–150
  23. Durand RE, Aquino-Parsons C. The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy. Radiother Oncol. 2006;80:138–142
  24. Eke I, Sandfort V, Mischkus A, Baumann M, Cordes N. Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. Radiother Oncol. 2006;80:178–184
  25. Handrick R, Rübel A, Faltin H, Eibl H, Belka C, Jendrossek V. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother Oncol. 2006;80:199–206
  26. Jaal J, Dörr W. Radiation-induced damage to mouse urothelial barrier. Radiother Oncol. 2006;80:250–256
  27. Klokov D, MacPhail SM, Banáth JP, Byrne JP, Olive PL. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol. 2006;80:223–229
  28. Krause M, Zips D, Thames HD, Kummermehr J, Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol. 2006;80:112–122[Epub 2006 August 17, Review]
  29. Lukacova S, Overgaard J, Alsner J, Horsman MR. Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models. Radiother Oncol. 2006;80:165–171
  30. Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol. 2006;80:192–198
  31. Raju U, Ariga H, Koto M, Lu X, Pickett J, Valdecanas D, et al. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiother Oncol. 2006;80:185–191
  32. Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, et al. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol. 2006;80:157–164
  33. Wissink EH, Verbrugge I, Vink SR, Schader MB, Schaefer U, Walczak H, et al. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother Oncol. 2006;80:214–222
  34. Bussink J, Kaanders JH, van der Kogel AJ. Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiother Oncol. 2007;82:10–17
  35. Ohneseit PA, Krebiehl G, Dittmann K, Kehlbach R, Rodemann HP. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro. Radiother Oncol. 2007;82:229–238
  36. Weppler SA, Krause M, Zyromska A, Lambin P, Baumann M, Wouters BG. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol. 2007;82:96–104
  37. West CM, Elliott RM, Burnet NG. The genomics revolution and radiotherapy. Clin Oncol (R Coll Radiol). 2007;19:470–480
  38. van Haaften G, Romeijn R, Pothof J, Koole W, Mullenders LH, Pastink A, et al. Identification of conserved pathways of DNA-damage response and radiation protection by genome-wide RNAi. Curr Biol. 2006;16:1344–1350
  39. Kasten-Pisula U, Vronskaja S, Overgaard J, Dikomey E. In normal human fibroblasts variation in DSB repair capacity cannot be ascribed to radiation-induced changes in the localisation, expression or activity of major NHEJ proteins. Radiother Oncol. 2008;86:321–328
  40. Vermeulen C, Verwijs-Janssen M, Begg AC, Vens C. Cell cycle phase dependent role of DNA repair and survival after ionizing radiation. Radiother Oncol. 2008;86:391–398
  41. Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother Oncol. 2006;78:138–145
  42. Jonathan RA, Wijffels KI, Peeters W, de Wilde PC, Marres HA, Merkx MA, et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol. 2006;79:288–297
  43. Jordan BF, Beghein N, Crokart N, Baudelet C, Grégoire V, Gallez B. Preclinical safety and antitumor efficacy of insulin combined with irradiation. Radiother Oncol. 2006;81:112–117
  44. Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol. 2006;81:130–135
  45. Wergin MC, Roos M, Inteeworn N, Laluhovà D, Allemann K, Kaser-Hotz B. The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome. Radiother Oncol. 2006;79:239–244
  46. Yaromina A, Zips D, Thames HD, Eicheler W, Krause M, Rosner A, et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol. 2006;81:122–129
  47. Fujii H, Sakata KI, Katsumata Y, Sato R, Kinouchi M, Someya M, et al. Tissue oxygenation in a murine SCC VII tumor after X-ray irradiation as determined by EPR spectroscopy. Radiother Oncol. 2008;86:354–360
  48. Tomita N, Shibamoto Y, Ito M, Ogino H, Sugie C, Ayakawa S, et al. Biological effect of intermittent radiation exposure in vivo: recovery from sublethal damage versus reoxygenation. Radiother Oncol. 2008;86:369–374
  49. Bayer C, Schilling D, Hoetzel J, Egermann HP, Zips D, Yaromina A, et al. PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. Radiother Oncol. 2008;86:361–368
  50. Sonveaux P. Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother Oncol. 2008;86:300–313
  51. Akudugu JM, Bell RS, Catton C, Davis AM, Griffin AM, O’Sullivan B, et al. Wound healing morbidity in STS patients treated with preoperative radiotherapy in relation to in vitro skin fibroblast radiosensitivity, proliferative capacity and TGF-beta activity. Radiother Oncol. 2006;78:17–26
  52. Brunner TB, Ernst-Stecken A, Jeske I, Grabenbauer GG, Sauer R, Distel L. Molecular verification of stereotactic radiotherapy in rats using ATMpS1981 immunofluorescence. Radiother Oncol. 2006;79:109–114
  53. Hill RP, Kaspler P, Griffin AM, O’Sullivan B, Catton C, Alasti H, et al. Studies of the in vivo radiosensitivity of human skin fibroblasts. Radiother Oncol. 2007;84:75–83
  54. Langan AR, Khan MA, Yeung IW, Van Dyk J, Hill RP. Partial volume rat lung irradiation: the protective/mitigating effects of Eukarion-189, a superoxide dismutase-catalase mimetic. Radiother Oncol. 2006;79:231–238
  55. Machtay M, Scherpereel A, Santiago J, Lee J, McDonough J, Kinniry P, et al. Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/bl6 mouse. Radiother Oncol. 2006;81:196–205
  56. Millar WT, Hopewell JW. Effects of very low dose-rate (90)Sr/(90)Y exposure on the acute moist desquamation response of pig skin. Radiother Oncol. 2007;83:187–195
  57. Arenas M, Gil F, Gironella M, Hernández V, Biete A, Piqué JM, et al. Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-beta(1) expression. Radiother Oncol. 2008;86:399–406
  58. Hehlgans S, Eke I, Deuse Y, Cordes N. Integrin-linked kinase: dispensable for radiation survival of three-dimensionally cultured fibroblasts. Radiother Oncol. 2008;86:329–335
  59. Borgmann K, Haeberle D, Doerk T, Busjahn A, Stephan G, Dikomey E. Genetic determination of chromosomal radiosensitivities in G0- and G2-phase human lymphocytes. Radiother Oncol. 2007;83:196–202
  60. Distel LV, Neubauer S, Keller U, Sprung CN, Sauer R, Grabenbauer GG. Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiother Oncol. 2006;81:257–263
  61. Söderlund K, Skoog L, Fornander T, Askmalm MS. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol. 2007;84:242–251
  62. Rødningen OK, Børresen-Dale AL, Alsner J, Hastie T, Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol. 2008;86:314–320
  63. Olive PL, Banath JP, Keyes M. Residual gammaH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy. Radiother Oncol. 2008;86:336–346
  64. Burlage FR, Roesink JM, Faber H, Vissink A, Langendijk JA, Kampinga HH, et al. Optimum dose range for the amelioration of long term radiation-induced hyposalivation using prophylactic pilocarpine treatment. Radiother Oncol. 2008;86:347–353
  65. Wanner G, Mayer C, Kehlbach R, Rodemann HP, Dittmann K. Activation of protein kinase Cepsilon stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. Radiother Oncol. 2008;86:383–390
  66. Dittmann K, Mayer C, Kehlbach R. The radioprotector Bowman-Birk proteinase inhibitor stimulates DNA-repair via epidermal growth factor receptor phosphorylation and nuclear transport. Radiother Oncol. 2008;86:375–382
  67. Bieler A, Mantwill K, Holzmüller R, Jürchott K, Kaszubiak A, Stärk S, et al. Impact of radiation therapy on the oncolytic adenovirus dl520: Implications on the treatment of glioblastoma. Radiother Oncol. 2008;86:419–427
  68. Dittmann K, Mayer C, Wanner G, Kehlbach R, Rodemann HP. The radioprotector O-phospho-tyrosine stimulates DNA-repair via epidermal growth factor receptor- and DNA-dependent kinase phosphorylation. Radiother Oncol. 2007;84:328–334
  69. Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG. PRIMA-1 radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol. 2008;86:407–411
  70. Haykal J, Fernainy P, Itani W, Haddadin M, Geara F, Smith C, et al. Radiosensitization of EMT6 mammary carcinoma cells by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide. Radiother Oncol. 2008;86:412–418
  71. Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?. Radiother Oncol. 2008;86:428–434

PII: S0167-8140(08)00089-3

doi: 10.1016/j.radonc.2008.02.004

Radiotherapy & Oncology
Volume 86, Issue 3 , Pages 295-299 , March 2008

Article Tools